SEC Form 4 · accession 0000950142-15-000894
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Andrew N Schiff
10% Owner
Steve Elms
10% Owner
Dennis J Purcell
10% Owner
Aisling Capital II LP
10% Owner
AISLING CAPITAL PARTNERS LLC
10% Owner
AISLING CAPITAL PARTNERS, LP
10% Owner
Period of report
Apr 23, 2015
Accepted (ET)
Apr 27, 2015 · 6:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 23, 2015 | S | 150,000 | $109.10 | D | 1,904,594 | I | By Aisling Capital II, L.P. |
| Common StockF1 | Apr 24, 2015 | S | 5,743 | $108.00 | D | 1,898,851 | I | By Aisling Capital II, LP |
| Common StockF1 | Apr 24, 2015 | S | 61,726 | $106.10 | D | 1,837,125 | I | By Aisling Capital II, LP |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling.